⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11519338 | 0.85 | — | — | |
| SCHEMBL30804410 | 0.81 | ADH1B (0.40) | — | |
| SCHEMBL17383354 | 0.81 | PRMT3 (0.32) | — | |
| SCHEMBL16269880 | 0.80 | — | — | |
| SCHEMBL10355798 | 0.79 | EPHX1 (0.45) | — | |
| SCHEMBL18602754 | 0.78 | — | — | |
| SCHEMBL21418095 | 0.78 | — | — | |
| Dimethylamine SCHEMBL634153 | 0.77 | TSHR (0.47) | — | |
| Dimethylamine SCHEMBL8774248 | 0.77 | TSHR (0.47) | — | |
| SCHEMBL17626634 | 0.76 | TSHR (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024049948-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND BCL-2 FAMILY INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-3762450-B1 | TREATMENT OF POWDER VARNISH WASTE FOR USE IN RECYCLING METHOD | UNIV BERLIN TECH (DE) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023215311-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR MODULATING A TARGET GENE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023196930-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | PURDUE RESEARCH FOUNDATION (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11530190-B2 | Compounds for treating mitochondrial disease | KHONDRION IP B.V. (NL) | 2022-12-20 | — | — | US | disclosed |
| WO-2021161887-A1 | COMPOUND | 住友化学株式会社 | 2021-08-19 | — | — | WO | disclosed |
| EP-3551617-B1 | COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS | COLUCID PHARMACEUTICALS INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-11053214-B2 | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists | COLUCID PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2021127452-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-1748786-A4 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | VICURON PHARM INC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20070249505-A1 | Viscoelastic Surfactant Fluids and Related Methods of Use | DAHAYANAKE MANILAL S | 2007-10-25 | — | — | US | disclosed |
| EP-1782127-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR | EASTMAN KODAK COMPANY (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1748786-A2 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | Vicuron Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006078277-A2 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | VICURON PHARMACEUTICALS INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006023667-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR | EASTMAN KODAK COMPANY (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1565201-A1 | METHODS OF ADMINISTERING DALBAVANCIN FOR TREATMENT OF BACTERIAL INFECTIONS | Vicuron Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046196-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS WITH PROTEIN-DALBAVANCIN COMPLEXES | VICURON PHARMACEUTICALS INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004045637-A1 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | VICURON PHARMACEUTICALS INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004045636-A1 | METHODS OF ADMINISTERING DALBAVANCIN FOR TREATMENT OF BACTERIAL INFECTIONS | VICURON PHARMACEUTICALS INC. (US) | 2004-06-03 | — | — | WO | disclosed |